Access cutting-edge kras mutant cancer treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access kras mutant cancer specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related kras mutant cancer treatment provided free
This phase II ComboMATCH treatment trial tests how well AMG 510 (sotorasib) with or without panitumumab works in treating patients with KRAS G12C mutant solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells. Pan
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this kras mutant cancer clinical trial in Palo Alto, CA
If you're searching for kras mutant cancer treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced kras mutant cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.